Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

On the second Wednesday of the month at 10 a.m., witness a special showcase of local spinners sharing how they craft fibers ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.